Oct 23, 2025 17:00
ZURA - Zura Bio Limited Class A Ordinary Shares
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 3.61 0.07 (1.94%) | 0.0 (0.0%) | 0.0 (-0.14%) | 0.03 (0.82%) | 0.13 (3.6%) | -0.02 (-0.54%) | -0.03 (-0.8%) | 0.01 (0.27%) |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- -0.17
- Diluted EPS:
- -0.17
- Basic P/E:
- -21.6471
- Diluted P/E:
- -21.6471
- RSI(14) 1m:
- 60.0
- VWAP:
- 3.68
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Sep 29, 2025 17:06
May 31, 2024 13:55
May 15, 2024 13:55
May 14, 2024 16:00
Oct 10, 2023 15:00
Aug 25, 2023 15:00
Aug 15, 2023 19:00
Jun 29, 2023 15:23
Jun 22, 2023 15:02